BSX: Boston Scientific Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Boston Scientific: 1-Year and 5-Year Forecast Outlook and Rating
Boston Scientific (BSX) has an immediate Buy & Keep consensus AI recommendation, based on 11 AI analysts.
The 1-year target is $46.0 for , with +9.58% expected return (+9.58% including net dividends) and a BUY rating.
The 5-year target is $72.4 for , with +72.46% expected return (+72.46% including net dividends) and a BUY rating.
Latest available market price: USD 42, as of 20 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Boston Scientific Flagship Insight
The Recovery Hinges on Retained Hospital Accounts, Not Restored Factories
Boston Scientific's recovery depends on converting restored manufacturing into retained hospital accounts and stronger cash generation. High consensus supports diversified procedural demand, but acquisition financing, integrated ablation competition and reimbursement restrictions limit valuation recovery. Deleveraging matters more than a return to former growth premiums.
How were the Investment Thesis and Forecasts created?
11 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Superintelligence (Anthropologist)
Universal Investor (Polymath)
Warren Buffett (Value Purist)
Michael Burry (Vulture)
Ray Dalio (Strategist)
Machiavelli (Insider)
Sherlock Holmes (Whistleblower)
Elon Musk (Visionary)
J.P. Morgan (Titan)
Ran across these frontier AI models
Google Gemini 4 Hydrogen
OpenAI GPT-6.1 Sol
Anthropic Claude Opus 5.5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Boston Scientific: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Boston Scientific at the latest market close (20 Nov 2026): $17,246 by Nov 2031 versus $14,502 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Boston Scientific is a commercial-repair investment, not simply a manufacturing restart. The base case combines resilient disposable-device demand, gradual throughput normalization and debt reduction after Penumbra, while assuming neither restored ablation exclusivity nor broad first-line WATCHMAN reimbursement. Valuation depends on recurring cash earnings: a disclosed tax benefit flatters trailing profits, and acquisition financing diverts cash before shareholders benefit. The strongest counterargument is that competing mapping ecosystems convert temporary hospital substitutions into permanent account losses. Current disclosures support partial rehabilitation, but the extent of underpricing remains conditional on retained accounts, disciplined reinvestment and demonstrable cash conversion rather than headline acquisition growth.
Key insights
- Debt repayment can increase equity value without multiple expansion, but only if acquired cash flows exceed financing, integration and continuing development costs.
- A recovering factory margin can coexist with weakening franchise economics when hospitals retain rival suppliers; clean operations therefore sharpen, rather than settle, attribution.
- Favorable clinical evidence creates an option, not booked revenue; reimbursement changes can unlock operating leverage, while premature development cuts jeopardize the competitive response.
Continue reading Boston Scientific analysis with Base subscription
See Base accessBoston Scientific: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 42, as of 20 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 11 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 13 Nov 2026 at USD 44.3. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|---|---|---|---|
| $42.5 | -4.23% | +1.24% | +1.24% | Guided fourth-quarter contraction and formal transition-year expectations outweigh manufacturing-restoration headlines. Investors must absorb weaker recurring momentum and acquisition funding demands before deciding whether depressed earnings represent a temporary trough or lasting commercial displacement across key hospital accounts. | $41.7 | $43.5 | $736 | |
| $43.0 | +1.27% | +2.43% | +2.43% | Cleaner operations and greater acquisition-financing clarity permit limited relief, but the evidence remains contested. Improving order throughput supports recovery expectations, while interest expense, integration dilution and continuing cardiac weakness prevent clearance alone from establishing a durable earnings inflection. | $40.1 | $44.7 | $724 | |
| $44.2 | +2.81% | +5.29% | +5.29% | A second cleaner reporting period tests whether reliable fulfillment translates into retained customers and stronger cash conversion. Diversified procedure growth and initial savings support stabilization, although continued electrophysiology erosion could still overwhelm the benefits of operational normalization. | $39.2 | $46.8 | $722 | |
| $46.0 | +3.95% | +9.58% | +9.58% | The outage anniversary improves comparisons as restructuring benefits become more visible. The stronger interpretation requires underlying account retention rather than merely easier revenue arithmetic, with early debt reduction and product-development progress supporting confidence that the transition is advancing. | $40.4 | $49.1 | $724 | |
| $48.0 | +4.42% | +14.34% | +14.34% | Annual guidance becomes the bridge from stabilization to renewed growth. Better cash conversion and anticipated catheter milestones support rehabilitation, while Penumbra financing remains an offset; the scenario does not require immediate share recapture or broad reimbursement expansion. | $42.0 | $51.6 | $735 | |
| $50.0 | +4.21% | +19.10% | +19.10% | Expected catheter commercialization and broader portfolio demand provide a clearer competitive test. Partial stabilization supports earnings revisions, but launch dates remain conditional and physician adoption must translate into recurring orders before improved technology warrants a meaningfully better valuation. | $44.1 | $53.7 | $752 | |
| $50.5 | +1.06% | +20.30% | +20.30% | Hospital contracting and device-pricing pressure restrain the recovery despite improving production economics. The balance favors continued operating progress, but competing platforms and tender discounts challenge optimistic margin assumptions and can temporarily interrupt the rebuilding of investor confidence. | $45.8 | $53.3 | $754 | |
| $52.8 | +4.43% | +25.77% | +25.77% | Dependable fulfillment and stronger cash conversion make acquisition-debt reduction more visible. Improved utilization supports earnings credibility, while the degree of valuation repair depends on whether cardiac accounts stabilize rather than simply benefit from favorable comparisons and cost reductions. | $47.7 | $55.4 | $780 | |
| $54.9 | +3.97% | +30.78% | +30.78% | A stronger annual cash record shifts attention toward sustained earnings contribution from vascular integration and product renewal. Lower financing leakage supports shareholders, although the scenario preserves uncertainty around integrated-ablation approvals and avoids assuming the full clinical pipeline succeeds. | $49.1 | $58.2 | $802 | |
| $56.5 | +3.04% | +34.59% | +34.59% | Existing-coverage WATCHMAN utilization and diversified interventional demand can sustain progress without a reimbursement breakthrough. Competitive catheter launches and Chinese procurement remain offsets, making realized earnings and debt repayment more persuasive than expansion of the theoretical patient market. | $50.6 | $59.6 | $819 | |
| $58.2 | +2.85% | +38.64% | +38.64% | Maturing integration and recurring consumable demand support incremental earnings gains as acquisition leverage becomes less restrictive. Continued development spending and routine pricing concessions absorb part of the improvement, keeping recovery grounded in cash delivery rather than aggressive capital returns. | $51.6 | $61.4 | $821 | |
| $60.1 | +3.41% | +43.16% | +43.16% | Restructuring completion and a longer record of dependable cash generation reduce execution uncertainty. Benefits increasingly accrue through operating efficiency and debt reduction, while renewed repurchases remain conditional on balance-sheet capacity rather than an automatic consequence of purchased revenue. | $53.1 | $64.5 | $842 | |
| $62.0 | +3.08% | +47.69% | +47.69% | Portfolio renewal and established procedure demand sustain the transition toward ordinary compounding. Longer-horizon structural-heart programs offer optionality, but their approvals and commercial economics remain uncertain; recurring cash generation carries more weight than assigning immediate value to unproven launches. | $54.7 | $67.1 | $863 | |
| $62.2 | +0.31% | +48.17% | +48.17% | Procurement negotiations and reimbursement scrutiny counter improving operating earnings, leaving limited room for valuation expansion. Lower debt service offers support, but repurchases and new investment must compete for cash rather than being assumed to accelerate simultaneously across the portfolio. | $55.8 | $66.7 | $871 | |
| $64.0 | +2.87% | +52.45% | +52.45% | Product refreshes, manufacturing productivity and diversified procedural demand help absorb hospital pricing pressure. The recovery remains credible if account economics stabilize, although prospective heart-pump revenues and associated funding obligations should not be treated as assured contributors to earnings. | $57.0 | $68.7 | $874 | |
| $65.8 | +2.80% | +56.74% | +56.74% | Deleveraging increasingly converts enterprise progress into value for common shareholders. Broad portfolio utilization supports cash earnings, while disciplined reinvestment preserves clinical relevance; another large debt-funded transaction would challenge the capital-allocation restraint underpinning this stage of the modeled recovery. | $58.1 | $70.4 | $896 | |
| $67.6 | +2.80% | +61.03% | +61.03% | Annual results increasingly reflect a normalized procedural business rather than outage recovery. Lower financing costs and steadier cash conversion support earnings quality, but mature competition limits the argument for restoring the exceptional valuation once attached to early category leadership. | $59.8 | $73.2 | $912 | |
| $69.1 | +2.27% | +64.60% | +64.60% | International vascular adoption and established cardiac utilization sustain moderate expansion as product cycles mature. Capital returns become more feasible after debt reduction, although ongoing research requirements and payer bargaining prevent all operating cash from becoming freely distributable shareholder proceeds. | $61.0 | $75.4 | $924 | |
| $70.6 | +2.11% | +68.18% | +68.18% | Attention shifts toward sustainable per-share cash generation as easier recovery comparisons fade. Continued clinical relevance supports the business, while maturing ablation competition and reimbursement discipline restrain additional valuation gains and keep growth dependent on execution rather than renewed exclusivity. | $62.3 | $77.6 | $939 | |
| $72.4 | +2.54% | +72.46% | +72.46% | The horizon closes with a diversified, less financially constrained procedural franchise in the favored scenario. Earnings and cash delivery dominate valuation, while lasting account displacement remains the principal reason rehabilitation could fall short despite restored operations and a broader portfolio. | $63.5 | $80.8 | $965 |
Show remaining 18 quartersCollapse to first 2 quarters
All 20 quarters are displayed in the table above.
Boston Scientific Stock Analysis & Scenarios Deep Dive
Boston Scientific: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Media coverage emphasizes repeated guidance cuts, contracting cardiac franchises and the coming earnings trough. Depressed valuation suggests diminished confidence, not proof that investors expect permanent decline. Analyst tallies in the inputs remain optimistic but differ by date and coverage, including stale estimates. The observable split is pessimistic trading versus expectations of an eventual rebound, rather than a verified unanimous public narrative.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd likely underestimates recovery value, implying modest conditional underpricing rather than a compelling immediate risk-adjusted gap. The overlooked connection is that recurring procedures across the diversified portfolio can support debt reduction even without renewed cardiac dominance. However, a tax-assisted earnings base and cash-heavy acquisition commitment make the apparent discount less generous. The investment consequence is an execution-dependent recovery case, not automatic valuation normalization. Permanent hospital-account losses are the strongest challenge, and optimistic analyst commentary shows that eventual rehabilitation is not wholly overlooked.
Repricing Catalyst
What could make the market recognize and close that gap? Two consecutive clean quarters of organic growth and improving cash conversion would distinguish customer retention from a mechanical factory restart. The most credible recognition window is mid-to-late 2027, after formal guidance and Penumbra financing clarify the earnings baseline. Early-2028 catheter milestones and subsequent integrated-platform progress could extend rehabilitation. Clearance alone is insufficient: financing absorption and retained accounts must support upward earnings revisions before modest underpricing can credibly close.
Boston Scientific: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Fear
- Volatility Regime
- Mixed
- Convergence Cycle Position
- Mixed
Fear is consistent across the reports, but expected trading behavior is materially split between orderly stabilization and an unfinished reversal. The decisive tension is whether cleared operational disruption establishes a floor or merely exposes permanent account losses, delaying thesis recognition.
Macro Regime Fit
Does the current market environment support the thesis? The supplied regime is mixed but financing-adverse. Elevated yields raise the cost of new Penumbra borrowing and constrain recovery multiples, while existing fixed-rate debt cushions immediate repricing. Recurring procedures are more resilient than hospital equipment budgets, but procurement pressure and Chinese tender pricing prevent defensive demand from guaranteeing earnings growth.
Advisor Disagreement
What do our AI Advisors disagree about most? The central economic disagreement is whether hospital substitutions reverse after service normalizes or become permanent losses to integrated ablation platforms. Recovery estimates also differ over how quickly Penumbra absorbs financing costs and releases cash for debt reduction. Broad WATCHMAN reimbursement is an upside event, not a necessary base-case assumption. Some margin disagreement is definitional: issuer materials distinguish GAAP from adjusted operating profitability. Analyst optimism also mixes dated estimates with current commentary. Two clean reporting quarters showing account retention, organic growth and cash conversion would resolve more than another restoration announcement.
Thesis Change
What changed in the thesis since the previous forecast? The recovery thesis remains intact, but current disclosures replace an early normalization story with a leveraged transition requiring sustained commercial proof. -- Previously, the discount was attributed mainly to temporary disruption and narrow franchise weakness. Current reports incorporate a stagnant standalone 2027 baseline and a longer ablation-product gap, delaying credible earnings rehabilitation. -- The September filing's tax benefit and cash-heavy acquisition obligations weaken the apparent valuation cushion. Diversified cash generation still supports recovery, but deleveraging and retained hospital accounts now dominate the investment case.
Boston Scientific: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Procedures outlast the growth reset | Sector And Industry | +28% | +26% | Recurring procedures, not equipment replacement cycles, underpin the diversified revenue base. Businesses outside electrophysiology and WATCHMAN continued growing through the outage, supported by coronary intervention and neuromodulation adoption. This breadth sustains earnings and cash generation during the cardiac reset, although it cannot fully offset persistent losses in high-margin franchises. |
| Throughput repair meets cost discipline | Operational Efficiency | +24% | +22% | Normalized production can recover stranded operating leverage before a major sales acceleration arrives. Lower disruption costs and the planned restructuring program support earnings and cash conversion through the transition. Savings should persist beyond the outage anniversary, but implementation spending and continuing security investment mean gross savings are not equivalent to distributable cash. |
| Vascular scale broadens the engine | Capital Allocation | +24% | +22% | Penumbra would add thrombectomy and neurovascular exposure to an established global hospital distribution network, diversifying growth away from contested cardiac lines. Conditional on clearance and integration, commercial scale supports multiyear revenue and earnings expansion. The strategic benefit is credible, but initial dilution and financing costs delay its translation into shareholder cash. |
| Product renewal defends clinical relevance | Innovation And Product | +20% | +18% | Continued investment in catheters, imaging, drug-coated balloons and neuromodulation sustains portfolio renewal rather than dependence on one franchise. Planned ablation updates address workflow weaknesses over the forecast horizon. The base case requires continued commercialization and partial competitive stabilization, not every approval arriving on schedule or former market dominance returning. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Mapping ecosystems erode catheter scarcity | Competitive Positioning | -16% | -14% | Integrated mapping-and-ablation competitors give hospitals credible alternatives and increase the cost of defending electrophysiology accounts. Recent sales contraction therefore cannot be attributed solely to disrupted shipments. Competitive contracts and selective discounting should persist across product cycles, reducing earnings and the valuation premium, even if procedure demand and company volumes eventually grow. |
| Acquisition growth pays lenders first | Capital Allocation | -14% | -12% | Penumbra's cash-heavy consideration adds financing and integration obligations before earnings contribution matures. New borrowing faces the supplied elevated-rate environment, while acquisition-related issuance can dilute per-share progress. Debt reduction consequently competes with repurchases and additional deals for several years, making current free cash flow an imperfect measure of cash available to shareholders. |
| Coverage gates and tenders tax innovation | Regulatory | -10% | -9.0% | Clinical evidence does not automatically become reimbursed procedures or protected pricing. WATCHMAN referral weakness may reflect procedure-mix and treatment choices more than lost device share, while CMS eligibility rules and Chinese procurement discounts restrict monetization. These continuing constraints slow revenue conversion and absorb part of the earnings benefit from innovation. |
| The cleanup outlasts the restart | Operational Efficiency | -8.0% | -7.0% | Restored systems do not eliminate the economic bill from cyber disruption and organizational repair. Continuing security investment, restructuring implementation and commercial remediation consume cash while customer service is rebuilt. These costs partly offset throughput savings, making a simple return to preincident margins too optimistic even without another shutdown. |
Boston Scientific: What Could Break or Accelerate the Thesis
Event Risk Score: Moderate 48/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Retenders crystallize permanent account losses | 35% | -35% | A major hospital contracting cycle during 2027-2028 could confirm that temporary supplier substitutions became permanent placements with rival integrated platforms. Repeated electrophysiology declines despite normalized fulfillment would identify the event. Lower utilization and defensive discounting would damage cash generation just as acquisition debt rises; established physician familiarity prevents treating this outcome as the base case. |
| Penumbra integration triggers credit downgrade | 25% | -30% | If post-close acquired cash generation misses integration milestones, a credit downgrade during 2028-2029 could turn a growth investment into a financing constraint. Wider spreads and slower debt reduction would force harder choices between development spending and shareholder distributions. Probability remains limited by diversified operating cash flow, but weak acquired economics would amplify the effect of existing cardiac pressure. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Coverage turns evidence into implants | 40% | +30% | A formal CMS decision broadening WATCHMAN eligibility during 2027-2029, alongside appropriate labeling and clinical adoption, could reopen referral channels beyond existing restrictions. Higher implant volumes would improve manufacturing absorption and salesforce productivity. Probability remains below an even chance because positive trial endpoints do not resolve payer scrutiny, procedural-risk debates or the pace of physician adoption. |
| Integrated ablation approval wins accounts | 35% | +25% | A clinically competitive FARAFLEX approval during 2028-2030, supported by durable safety and workflow performance, could turn product renewal into meaningful hospital-account gains. Success would strengthen recurring catheter revenue and justify a better earnings multiple. Probability remains limited because regulatory execution and displacement of entrenched rival mapping systems must both succeed, beyond merely stabilizing existing business. |
Company Financial AnalysisBoston Scientific: Earnings and Financials Analysis by AI
Financial figures available as of Nov 16, 2026. Only filings and source records available by this analysis date are included. View latest Boston Scientific financials here.
Earnings and financials
Boston Scientific's October 2026 earnings release shows a sharp slowdown, with third-quarter sales growth around 1.5%. Cyber disruption hurt manufacturing and shipments, but weaker electrophysiology and WATCHMAN demand means the deterioration was not simply an interrupted delivery schedule. The September filing also identifies a first-quarter tax benefit that makes trailing profits look stronger than recurring operations. The supplied trailing free cash flow of $3.33 billion shows that the company still generates substantial cash, although less than in the previous fiscal year. That supports recovery and debt repayment, not an immediate return to rapid growth. The unresolved question is how much customer demand returns after reliable service resumes.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 20.1B | USD 2.9B | USD 3.7B |
| 2024 | USD 16.7B | USD 1.9B | USD 2.6B |
| 2023 | USD 14.2B | USD 1.6B | USD 1.7B |
| 2022 | USD 12.7B | USD 698M | USD 914M |
| 2021 | USD 11.9B | USD 1B | USD 1.3B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 49.4x | TTM | Native | USD / USD |
| 2024 | 71.8x | TTM | Native | USD / USD |
| 2023 | 53.6x | TTM | Native | USD / USD |
| 2022 | 95.6x | Annual | Native | USD / USD |
| 2021 | 58.7x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Issuer third-quarter 2026 materials distinguish a 16.1% GAAP operating margin from a 26.5% adjusted operating margin. Both weakened, so the deterioration cannot be dismissed as accounting noise. Idle production, weaker cost absorption and product-liability charges interrupted the earlier improvement in profitability. Some pressure should fade as manufacturing runs normally, but the old margin level is not a guaranteed floor. Competitive catheter pricing, weaker cardiac product mix and Chinese procurement discounts can persist after systems recover. Restructuring offers an offset, although implementation and security spending consume part of the benefit. Better cash generation alongside improving margins would provide stronger evidence of repair than adjusted earnings alone.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 4B | 19.8% | 14.4% |
| 2024 | USD 2.6B | 15.7% | 11.1% |
| 2023 | USD 2.2B | 15.3% | 11.2% |
| 2022 | USD 1.8B | 14.4% | 5.5% |
| 2021 | USD 1.9B | 16.2% | 8.7% |
Balance sheet and leverage
The September 2026 Form 10-Q reports approximately $12.0 billion of gross debt against $0.61 billion of unrestricted cash. This is a net-debt business with strong cash generation, not a cash-rich turnaround. Existing fixed-rate borrowing cushions immediate interest-rate changes, but it does not remove the cost of financing pending acquisitions. Penumbra's cash-heavy consideration adds obligations before its earnings contribution matures. Buybacks, development spending, restructuring and debt reduction consequently compete for the same resources. Goodwill and acquired technology also make accounting equity a poor measure of readily available protection. The balance sheet appears serviceable, but the recovery case depends on prioritizing debt reduction rather than assuming unrestricted capital returns.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 12.4B | USD 2B | USD 10.4B net debt | USD 10.4B | 1.62x |
| 2024 | USD 11.1B | USD 414M | USD 10.7B net debt | USD 10.7B | 1.08x |
| 2023 | USD 9.5B | USD 865M | USD 8.6B net debt | USD 8.6B | 1.32x |
| 2022 | USD 9.3B | USD 928M | USD 8.4B net debt | USD 8.4B | 1.51x |
| 2021 | USD 9.5B | USD 1.9B | USD 7.5B net debt | USD 7.5B | 1.48x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The supplied FY2025 financials show factory investment near 4.4% of revenue alongside $2.05 billion of research spending. Boston Scientific therefore invests heavily in clinical evidence and product development without needing unusually large physical facilities. Cutting development too deeply would protect today's profits while weakening the response to competing cardiac systems. The larger funding decisions sit outside ordinary factory spending. Issuer materials describe Penumbra, MiRus investment rights and development partnerships, while restructuring and cyber resilience require additional cash. Blackstone co-funding reduces near-term development demands but shares future product economics. Low factory spending should therefore not be mistaken for a business with few investment obligations or abundant cash available for repurchases.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 876M | USD 2.1B |
| 2024 | USD 790M | USD 1.6B |
| 2023 | USD 800M | USD 1.4B |
| 2022 | USD 612M | USD 1.3B |
| 2021 | USD 554M | USD 1.2B |
Behind the synthesisBoston Scientific: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 11 advisor opinions. The weights and rationales below are retained from that synthesis.
Issuer disclosures, the September filing, FDA approval records and CMS coverage rules support a common causal pattern: diversified procedure demand survives, but restored manufacturing does not automatically recover hospital allocations. Acquisition financing and continuing reimbursement restrictions make cash conversion more informative than headline revenue or trailing earnings. Most reports reuse the same outage, cash-flow and restructuring figures; repetition is not independent confirmation. Greater weight therefore goes to analyses that distinguish recurring earnings, margin definitions and commercial retention, alongside the credible cautious case that lenders absorb much of the initial recovery. Lower weights reflect automatic buyback assumptions, insider-based valuation floors, speculative enforcement claims and overly precise launch schedules. The strongest unresolved issue is whether clean operations reveal temporary shipment disruption or permanent account displacement. Tax normalization and acquisition obligations narrow the apparent valuation cushion without negating recovery potential.
Individual targets retain their original dates. Returns and ratings use the same latest available market close and dividend assumptions as the Consensus.
All 11 opinions
Consensus weight Allocation: 17.0/100. Weight Allocation Rationale: Direct filing, issuer, FDA and CMS references support unusually careful distinctions between restored operations, retained customers and reimbursed demand. Normalizing the tax benefit strengthens valuation discipline. Its relatively generous terminal multiple and speculative contracting-quarter timing remain limitations; shared primary sources also prevent treating its evidence as wholly independent.
The 1-year target is $49.2 for , with +17.12% expected return and a STRONG BUY rating. The 5-year target is $80.8 for , with +92.44% expected return and a STRONG BUY rating.
Consensus weight Allocation: 17.0/100. Weight Allocation Rationale: Issuer-backed margin definitions, fixed-rate debt distinctions and emphasis on commercial retention provide strong causal grounding. The refusal to equate clinical success with reimbursement deserves substantial weight. Evidence overlaps another well-documented report, and terminal profitability remains demanding, so this allocation reflects analytical consistency rather than independent confirmation or presumed forecasting skill.
The 1-year target is $48.8 for , with +16.15% expected return and a STRONG BUY rating. The 5-year target is $72.8 for , with +73.33% expected return and a BUY rating.
Consensus weight Allocation: 15.0/100. Weight Allocation Rationale: The distinction between durable core cash generation and acquisition-constrained shareholder distributions is economically coherent. Its restrained recovery assumptions deserve substantial weight. Many supporting figures recur elsewhere rather than independently corroborate the thesis, while precise leverage milestones and product-launch outcomes remain conditional.
The 1-year target is $45.6 for , with +8.70% expected return and a BUY rating. The 5-year target is $69.1 for , with +64.51% expected return and a BUY rating.
Consensus weight Allocation: 11.0/100. Weight Allocation Rationale: The strongest cautious contribution connects pro-forma valuation, acquisition debt and limited freely distributable cash. That argument merits meaningful weight despite overlapping sources. Its near-term compression scenario is not independently established, and weak tangible book value does not prove low franchise value, tempering the otherwise credible balance-sheet challenge.
The 1-year target is $40.4 for , with -3.79% expected return and a SELL ALL rating. The 5-year target is $63.5 for , with +51.32% expected return and a BUY rating.
Consensus weight Allocation: 10.0/100. Weight Allocation Rationale: The separation of diversified growth from troubled cardiac franchises and attention to nonrecurring earnings improve the analysis. Detailed source references aid traceability. However, operating-margin labels conflict with issuer-backed definitions elsewhere, and the fixed-exchange-ratio acquisition discount requires qualification. These weaknesses reduce confidence in its numerical calibration.
The 1-year target is $47.0 for , with +11.85% expected return and a BUY rating. The 5-year target is $74.5 for , with +77.52% expected return and a BUY rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: Integrated mapping competition provides a credible explanation for electrophysiology weakness, and the delayed recovery recognizes financing costs. Weight is limited by overlapping secondary sources, confident market-share assertions and restructuring milestones that run ahead of the stated program timetable. Technological resilience alone does not establish commercial recovery.
The 1-year target is $43.8 for , with +4.45% expected return and a NEUTRAL rating. The 5-year target is $69.6 for , with +65.89% expected return and a BUY rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: Attention to tax-distorted earnings, restructuring cash costs and acquisition leverage supports a cautious recovery path. Its sources mostly overlap other reports. Assertions that trial findings preclude first-line expansion, or that clearance requires no divestitures, exceed the available evidence and limit weight despite the credible financing critique.
The 1-year target is $43.8 for , with +4.40% expected return and a NEUTRAL rating. The 5-year target is $66.3 for , with +57.90% expected return and a BUY rating.
Consensus weight Allocation: 6.0/100. Weight Allocation Rationale: The connection between acquisition financing, restrictive rates and procedural resilience is sound. Its sources substantially overlap the common evidence pool, limiting incremental corroboration. Accelerated launch assumptions and some early savings realization introduce avoidable optimism, although the underlying distinction between operational recovery and structural pricing pressure remains useful.
The 1-year target is $45.6 for , with +8.71% expected return and a BUY rating. The 5-year target is $71.8 for , with +70.95% expected return and a BUY rating.
Consensus weight Allocation: 5.0/100. Weight Allocation Rationale: The durable-procedure and delayed-product-cycle arguments survive scrutiny and correctly recognize acquisition dilution. Much supporting evidence repeats common sources, however, while confident competitor-entry dates, covenant interpretations and rapid deleveraging assumptions are insufficiently established. The useful economic mechanism receives weight without adopting the stronger biological-obsolescence framing.
The 1-year target is $44.7 for , with +6.51% expected return and a NEUTRAL rating. The 5-year target is $76.0 for , with +80.96% expected return and a BUY rating.
Consensus weight Allocation: 4.0/100. Weight Allocation Rationale: Regulatory clearance and development-funding commitments are relevant to capital flexibility. Lower weight reflects unsupported claims that insider purchases establish a downside floor, speculative political enforcement assumptions and ambitious pipeline contributions. The source list does not independently substantiate the stronger causal claims connecting those signals to shareholder protection.
The 1-year target is $44.3 for , with +5.41% expected return and a NEUTRAL rating. The 5-year target is $78.9 for , with +87.96% expected return and a STRONG BUY rating.
Consensus weight Allocation: 1.0/100. Weight Allocation Rationale: The small nonzero allocation preserves the supported insight that recurring procedures and research investment sustain cash generation. No research receipts accompany the report, and its path largely omits the already committed Penumbra financing burden while assuming continuing share retirement. Those omissions materially weaken its capital-allocation and valuation assumptions.
The 1-year target is $47.9 for , with +14.21% expected return and a STRONG BUY rating. The 5-year target is $72.6 for , with +72.83% expected return and a BUY rating.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v9 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Boston Scientific forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Sources retained from AI Researcher searches
Asset-specific · Researcher web40 available sources from this batch (113 recorded). The first 15 are shown below; expand to read the rest.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- sec.gov sec.gov
- fda.gov fda.gov
- Percutaneous Left Atrial Appendage Closure (LAAC) | CMS cms.gov
- Sphere‐9 Catheter and Affera Ablation System - P240013 | FDA fda.gov
- bsx-20260930 sec.gov
- BOSTON SCIENTIFIC CORP - Form 8-K - FY2026 sec.gov
- file: ss5910887_425.htm sec.gov
- www.sec.gov sec.gov
- www.sec.gov sec.gov
- bostonscientific.com bostonscientific.com
- medtechdive.com medtechdive.com
- perplexity.ai perplexity.ai
- investing.com investing.com
- biggo.com biggo.com
- mddionline.com mddionline.com
Show 25 more sources
- deepresearchglobal.com deepresearchglobal.com
- stocktitan.net stocktitan.net
- marketbeat.com marketbeat.com
- massdevice.com massdevice.com
- thecapitolforum.com thecapitolforum.com
- tradingview.com tradingview.com
- cardiovascularbusiness.com cardiovascularbusiness.com
- fool.com fool.com
- gurufocus.com gurufocus.com
- substack.com substack.com
- tradingkey.com tradingkey.com
- tickeron.com tickeron.com
- trefis.com trefis.com
- youtube.com youtube.com
- aurelionresearch.com aurelionresearch.com
- fitchratings.com fitchratings.com
- fortune.com fortune.com
- spglobal.com spglobal.com
- zacks.com zacks.com
- 44international.com 44international.com
- acc.org acc.org
- baptistaresearch.com baptistaresearch.com
- baserealitygroup.com baserealitygroup.com
- betafinch.com betafinch.com
- blackstone.com blackstone.com
73 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2026 Year-to-Date Global Market and World-Events Context Through November 14
Download Archived SnapshotCoverage 2026-01-01 to 2026-11-14 · Knowledge cutoff 2026-11-14
January 1-November 14, 2026: persistent inflation, partial oil supply recovery, US midterms and trade, AI financing, and uneven growth.
Archived context covering 2026-01-01 to 2026-11-14. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 96K bytes
- Words
- 14.2K words
- Characters
- 96K characters
- Est. tokens (characters ÷ 4)
- 24K tokens
Fed held at 3.75%-4.00%; Democrats won the next Congress, Nvidia changed leadership and Anthropic filed preliminary IPO terms. Markets through November 13.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| US tariff reset, trade truce and incoming divided government | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-12-31–2026-09-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.
Boston Scientific: forecast questions
What is Boston Scientific (BSX)'s 1-year price forecast?
Boston Scientific's 1-year target is $46.0 for Nov 2027. The current AI rating is BUY. The expected return from the recorded close is +9.58%, or +9.58% modeled return including net dividends. Latest available market price: USD 42, as of 20 Nov 2026. The target date is fixed at publication.
What is Boston Scientific (BSX)'s 5-year price forecast?
Boston Scientific's 5-year target is $72.4 for Nov 2031. The current AI rating is BUY. The expected return from the recorded close is +72.46%, or +72.46% modeled return including net dividends. Latest available market price: USD 42, as of 20 Nov 2026. The target date is fixed at publication.
How can I compare the AI opinions and audit past Boston Scientific forecasts?
11 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History lists the available batches with their original publication dates.
How does an AI-generated forecast for Boston Scientific differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Boston Scientific is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
If iPulse AI produces thousands of investment reports - work estimated to require over 100,000 traditional analyst hours - isn't that just "AI slop" at scale?
No. iPulse AI produces AI-generated research at scale, but the purpose is depth of analysis, comparison, and accountability. The number of reports is a consequence of the research process; it is not the goal.
iPulse AI does not produce thin copies of existing websites, articles, or investment reports. We use frontier models as an Analytical Intelligence layer. Our Financial Experts select, validate, curate, and supply the input data, including proprietary inputs, so the models work from a prepared evidence base.
In Researcher mode, models can also search the web to check current information, test assumptions, and investigate evidence that may be missing from the supplied data. This can include lobbying expenditure, management developments, regulatory decisions, or other facts relevant to a particular investment thesis. Thinker mode focuses on deep reasoning over the supplied data and context.
Our process goes much further than asking ChatGPT to evaluate a stock. Our team designs structured investment frameworks inspired by the approaches of influential investors, economists, political thinkers, and technological visionaries. These are AI analytical frameworks, not reports written or endorsed by the people who inspired them.
Each asset is analyzed separately through multiple frameworks and configurations, using specialized inputs and task instructions. Different perspectives examine different questions: valuation, business quality, technological disruption, macroeconomic conditions, political influence, financial risks, and more.
Cloud infrastructure allows these workflows to run at scale. That scale also comes with quality assurance at scale: up to 30% of report-generation attempts fail our QA checks. We rerun failed attempts until a clean report passes those checks. Users are presented only with reports that have passed QA.
This explains the volume. The value comes from what we do with the analysis.
A second layer synthesizes the individual reports into an asset-level consensus. This is where we recommend starting when researching a particular asset: it brings together the central thesis, supporting evidence, risks, and disagreements while preserving access to the underlying opinions.
We then compare assets through our proprietary iPulse AI Consensus Score, whose methodology is publicly explained. This helps users move from understanding one asset to comparing opportunities across the analyzed universe.
A further research and editorial layer examines leading candidates, checks current evidence, and develops focused Editorial Top Picks across broad-market and dedicated asset categories. Human editors review the evidence and approve each published edition. For example, explore our Best Long-Term Investments.
But the process does not end when a report is published. We preserve past forecasts so users with the relevant subscription can inspect what the system actually said and compare it with subsequent market outcomes. As more forecasts reach their target dates, the historical record becomes more useful for evaluating which approaches worked, which failed, and under what conditions.
We publish research on our website, arXiv, and Zenodo, alongside explanatory writing on Medium. We use the evidence to refine our data, frameworks, validation, and workflows, and document important findings in Lessons Learned.
The standard we ask users to judge us by is the reasoning, evidence, and historical record behind the research.
How does the iPulse AI Engine work?
The engine runs AI advisor configurations against a shared set of research inputs. The engine history explains the research workflow and what changed between versions.








